Creatinine-Cystatin C eGFR Discordance During Incretin-Based Weight Loss: A Narrative Review of Current Evidence and Clinical Implications

Authors

  • Rodrigo Fernando Ale Chura Department of Primary Care, Universidad Católica de Santa María, Arequipa, Perú Author
  • Néstor Manuel Galindo Pupo Department of Internal Medicine/Critical Care, Universidad Cooperativa de Colombia, Florencia, Colombia Author
  • Guadalupe Estrada Cerón Faculty of Medicine, Universidad Veracruzana, Veracruz, Mexico Author
  • Jaime Andrés Vásquez González Department of Internal Medicine, Universidad San Sebastián, Los Ángeles, Chile Author
  • Fausto Martínez Morales Pathophysiology Department, Universidad Autónoma Benito Juárez de Oaxaca, Oaxaca, Mexico Author
  • Celine Lucero Ludwig Hernández Faculty of Medicine, Independent Researcher, Puebla, Mexico Author

DOI:

https://doi.org/10.66687/jebmr.2.03.2026.49

Keywords:

Cystatin C, Creatinine, estimated glomerular filtration rate, GLP-1 receptor agonist, tirzepatide, semaglutide, chronic kidney disease, body composition, sarcopenia

Abstract

Background: Glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists lead to significant and durable weight loss, associated with quantifiable levels of decrease in lean and skeletal muscle mass, decreased food intake, and decreased levels of systemic inflammation. This change in non-glomerular filtration rate (non-GFR) factors that affect each biomarker (creatinine by muscle mass and protein intake, and tubular secretion; cystatin C by adiposity, inflammation, and metabolic status) suggests that observed trajectories during weight loss related to incretin based drugs may be partially due to these changes, and not just the changes in estimated glomerular filtration rate (eGFR).

Objective: This review critically evaluates the physiological basis and limitations of various equations measuring cross-sectionally the eGFR from creatinine, cystatin C, or both, and summarizes 2020-2026 data from peer-reviewed evidence regarding the effect of weight loss induced by incretin-based therapy on eGFR and/or biomarkers.

Results: Findings of discordance vary and in some direct dual-marker studies, such as the SURPASS-4 post hoc analysis, the analysis of the kidney parameters in the SURMOUNT-1/2 randomized trials, and the SUMMIT and SMART randomized trials, no correlation between discordance and body-composition change was observed; conflicting or opposing discordance findings were reported in certain incretin-treated populations, such as the analysis of the kidney parameters in the SURMOUNT-2 randomized trial. The evidence from the bariatric surgery literature, and the sarcopenia/cachexia literature, is more consistent with that of muscle mass loss leading to slight overestimation of eGFR using creatinine as compared to eGFR using cystatin C, and as compared to measured GFR.

Conclusion: Current data do not show that either marker better tracks true kidney function during incretin-induced weight loss; where an accurate GFR matters, such as dosing of renally cleared drugs, combined-marker eGFR or measured GFR should be considered.

References

1. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563

2. Look M, Skarbaliene J, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. doi:10.1111/dom.16275

3. Arslan S. Medical nutrition in the glucagon-like peptide-1 (GLP-1) era: protein strategies, micronutrient monitoring, and lean mass preservation. Clin Nutr ESPEN. 2026;73:103305. doi:10.1016/j.clnesp.2026.103305

4. Kanbay M, et al. Effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists on inflammatory and metabolic biomarkers in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2026;28(10):9002-9013. doi:10.1111/dom.71106

5. Ren Y, et al. The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: a systematic review and meta-analysis. Diabetes Obes Metab. 2025;27(7):3607-3626. doi:10.1111/dom.16366

6. Bray JJH, Foster-Davies H, Salem A, et al. Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2021;23(8):1806-1822. doi:10.1111/dom.14399

7. Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis. Front Endocrinol. 2026;16:1734549. doi:10.3389/fendo.2025.1734549

8. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109-121. doi:10.1056/NEJMoa2403347

9. Mann JFE, et al. Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis. Lancet Diabetes Endocrinol. 2026;14(10):818-830. doi:10.1016/S2213-8587(26)00134-8

10. Heerspink HJL, et al. Kidney parameters with tirzepatide in obesity with or without type 2 diabetes. J Am Soc Nephrol. 2025;36(11):2190-2200. doi:10.1681/ASN.0000000764

11. Gil-Lopez F, et al. Evaluation of kidney function in cirrhosis: methods and pitfalls. Diagnostics (Basel). 2026;16(13):2088. doi:10.3390/diagnostics16132088

12. Delgado C, Baweja M, Crews DC, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. J Am Soc Nephrol. 2021;32(12):2994-3015. doi:10.1681/ASN.2021070988

13. Patel S, et al. Cystatin C in chronic kidney disease: enhancing diagnostic accuracy and patient outcomes. Postgrad Med. 2026;138(2):136-145. doi:10.1080/00325481.2026.2634426

14. Laucyte-Cibulskiene A, Nilsson PM, Engström G, Christensson A. Increased fat mass index is associated with decreased glomerular filtration rate estimated from cystatin C. Data from Malmö Diet and Cancer cohort. PLoS One. 2022;17(7):e0271638. doi:10.1371/journal.pone.0271638

15. Cong X, Chen X, Shen Q, Wu Y, Wang Q, Chen L. Serum cystatin C levels increase with increasing visceral fat area in patients with type 2 diabetes mellitus. Sci Rep. 2024;14:18638. doi:10.1038/s41598-024-69623-w

16. Sineglazova AV, et al. Sex differences in early stages of cardiorenometabolic syndrome in young adults. Cureus. 2025;17(10):e93900. doi:10.7759/cureus.93900

17. Mizuta M, Fukuda M, Fujii M, et al. Chronic kidney disease with Sjögren's syndrome and hyperthyroidism: discrepant creatinine- and cystatin C-based eGFR. Intern Med. 2026. doi:10.2169/internalmedicine.7902-26

18. Gutiérrez OM, Sang Y, Grams ME, et al. Association of estimated GFR calculated using race-free equations with kidney failure and mortality by Black vs non-Black race. JAMA. 2022;327(23):2306-2316. doi:10.1001/jama.2022.8801

19. Furth SL, et al. The relationship between obesity and chronic kidney disease: conclusions from a KDIGO Controversies Conference. Kidney Int. 2025;109(3):442-464. doi:10.1016/j.kint.2025.09.019

20. Awdishu L, Karger AB, Shlipak MG, Estrella MM. Use of cystatin C in tandem with creatinine to improve GFR estimation and clinical decision making. J Am Soc Nephrol. 2026;37(9):2042-2054. doi:10.1681/ASN.0000001201

21. Osredkar J, Klemenčič I, Kumer K, Pajek J, Knap B. Comparison of creatinine-, cystatin C-, and combined creatinine-cystatin C-based equations for estimating glomerular filtration rate: a real-world analysis in patients with chronic kidney disease. Int J Mol Sci. 2025;27(1):364. doi:10.3390/ijms27010364

22. Hage M, et al. Assessment of GFR estimation methods in patients with obesity. J Clin Endocrinol Metab. 2026;111(3):679-688. doi:10.1210/clinem/dgaf510

23. Sangla F, Marti PE, Verissimo T, Pugin J, de Seigneux S, Legouis D. Measured and estimated glomerular filtration rate in the ICU: a prospective study. Crit Care Med. 2020;48(12):e1232-e1241. doi:10.1097/CCM.0000000000004650

24. Groothof D, Post A, Polinder-Bos HA, et al. Muscle mass and estimates of renal function: a longitudinal cohort study. J Cachexia Sarcopenia Muscle. 2022;13(4):2031-2043. doi:10.1002/jcsm.12969

25. Hanna PE, Ouyang T, Tahir I, et al. Sarcopenia, adiposity and large discordance between cystatin C and creatinine-based estimated glomerular filtration rate in patients with cancer. J Cachexia Sarcopenia Muscle. 2024;15(3):1187-1198. doi:10.1002/jcsm.13469

26. Al Ozairi E, et al. Weight loss-dependent changes in body composition and bone health in people with obesity and type 1 diabetes treated with liraglutide, semaglutide, or tirzepatide. Diabetes Metab Res Rev. 2026;42(6):e70213. doi:10.1002/dmrr.70213

27. Chang AR, George J, Levey AS, Coresh J, Grams ME, Inker LA. Performance of glomerular filtration rate estimating equations before and after bariatric surgery. Kidney Med. 2020;2(6):699-706. doi:10.1016/j.xkme.2020.08.008

28. Friedman AN, et al. Measurement, estimation, and correlates of the GFR before and after bariatric surgery. J Am Soc Nephrol. 2025;37(1):110-119. doi:10.1681/ASN.0000000797

29. Teixeira Silva PR, et al. Effects of high-protein diets on renal function and body composition in adults without chronic kidney disease: a systematic review and meta-analysis of randomised trials. Diabetes Obes Metab. 2026;28(9):7672-7683. doi:10.1111/dom.70996

30. Li J, Yang L, Yang B, et al. Dietary patterns and kidney health: an umbrella review of systematic reviews and meta-analyses. Nutr Rev. 2026;84(9):1903-1921. doi:10.1093/nutrit/nuaf208

31. Heerspink HJL, Soler M, Beernink JM, et al. Effects of semaglutide on body composition and GFR: a prespecified analysis of the SMART trial. Clin J Am Soc Nephrol. 2026;21(7):1149-1158. doi:10.2215/CJN.0000001051

32. Heerspink HJL, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on cystatin C-based kidney function: a SURPASS-4 post hoc analysis. Diabetes Care. 2023;46(8):1501-1506. doi:10.2337/dc23-0261

33. Packer M, Zile MR, Kramer CM, et al. Interplay of chronic kidney disease and the effects of tirzepatide in patients with heart failure, preserved ejection fraction, and obesity: the SUMMIT trial. J Am Coll Cardiol. 2025;85(18):1721-1735. doi:10.1016/j.jacc.2025.03.009

34. Yahya R, Iversen E, Sivalingam S, et al. Effect of semaglutide on measured vs estimated glomerular filtration rate. Nephrol Dial Transplant. 2026. doi:10.1093/ndt/gfag154

35. van Ruiten CC, van der Aart-van der Beek AB, IJzerman RG, et al. Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: a prespecified secondary analysis of a randomized controlled clinical trial. Diabetes Obes Metab. 2021;23(8):1851-1858. doi:10.1111/dom.14410

36. Redouane B, Greene SJ, Fudim M, et al. Effects of liraglutide on worsening renal function among patients with heart failure with reduced ejection fraction: insights from the FIGHT trial. Circ Heart Fail. 2020;13(5):e006758. doi:10.1161/CIRCHEARTFAILURE.119.006758

37. Kusunoki H, Tsuji S, Kusukawa T, et al. Relationships between cystatin C- and creatinine-based eGFR in Japanese rural community-dwelling older adults with sarcopenia. Clin Exp Nephrol. 2020;25(3):231-239. doi:10.1007/s10157-020-01981-x

38. Iacomelli I, Giordano A, Rivasi G, et al. Low creatinine potentially overestimates glomerular filtration rate in older fracture patients: a plea for an extensive use of cystatin C? Eur J Intern Med. 2020;84:74-79. doi:10.1016/j.ejim.2020.06.016

39. Awdishu L, et al. KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: a primer on what pharmacists need to know. Am J Health Syst Pharm. 2025;82(12):660-671. doi:10.1093/ajhp/zxaf044

40. Pelz S, Kobelt I, Schettle M, Hertler C, Blum D. Discrepancies between creatinine- and cystatin C-based eGFR estimation in palliative care patients and their implications on drug dosing. J Palliat Med. 2026;29(6):723-732. doi:10.1177/10966218261423788

41. Costa E Silva VT, Sise ME, Inker LA, et al. Impact of computed tomography-derived body composition analysis on the performance of GFR estimating equations in patients with cancer. Clin J Am Soc Nephrol. 2026;21(2):261-272. doi:10.2215/CJN.0000000878

42. Gama RM, et al. Measuring or estimating glomerular filtration rate in potential kidney donors: a comparative study. Clin Kidney J. 2026;19(9):sfag250. doi:10.1093/ckj/sfag250

43. Sinhmar P, Girimaji NS, Kumar D. Evaluation of kidney function in living kidney donor candidates. Curr Opin Organ Transplant. 2026;31(3):111-116. doi:10.1097/MOT.0000000000001282

44. Yajima S, Nakanishi Y, Ogasawara RA, et al. Value of cystatin C-based sarcopenia index in patients undergoing surgery for renal tumors. Clin Genitourin Cancer. 2024;22(3):102051. doi:10.1016/j.clgc.2024.02.002

45. Tuccinardi D, Masi D, Watanabe M, et al. Precision obesity medicine: a phenotype-guided framework for pharmacologic therapy across the lifespan. J Endocrinol Invest. 2025;48(12):2761-2798. doi:10.1007/s40618-025-02700-7

Downloads

Published

2026-11-18

How to Cite

Creatinine-Cystatin C eGFR Discordance During Incretin-Based Weight Loss: A Narrative Review of Current Evidence and Clinical Implications. (2026). Journal of Evidence-Based Medical Research, 2(03), 96-104. https://doi.org/10.66687/jebmr.2.03.2026.49

Similar Articles

1-10 of 19

You may also start an advanced similarity search for this article.